Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: In situaromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

Figure 2

Time to progression (TTP) according to high, low and negative expression of COX-2 and Aromatase in primary tumor tissue for patients treated with either letrozole (black) or tamoxifen (grey). (A) TTP according to COX-2 expression: Letrozole treatment, COX-2 high, n = 6; COX-2 low, n = 22; COX-2 negative, n = 13. Tamoxifen treatment, COX-2 high, n = 7; COX-2 low, n = 14; COX-2 negative, n = 11. (B) TTP according to Aromatase expression: Letrozole treatment, Aromatase high, n = 4; Aromatase low, n = 27; Aromatase negative, n = 10. Tamoxifen treatment, Aromatase high, n = 4; Aromatase low, n = 25; Aromatase negative, n = 4.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us